U.S. scientists used a chip called DMET, or drug-metabolizing enzymes, to identify genetic variations associated with the efficacy and toxicity of drugs. "This type of turn-key testing, if validated, could eventually replace highly specialized, time-consuming and labor-intensive testing -- thus allowing more institutes the opportunity to pursue genotyping and pharmocogenetic research," one of the researchers said.

Related Summaries